TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00042289

Intervention type: DRUG
Intervention: abacavir
Description: abacavir 300mg twice a day
Study: NCT03487484

Intervention type: BEHAVIORAL
Intervention: Faecal Incontinence Score
Description: To assess faecal incontinence, the Vaizey Wexner questionnaire will be applied

Intervention type: BEHAVIORAL
Intervention: Faecal Incontinence Score
Description: To assess faecal incontinence, the Vaizey Wexner questionnaire will be applied
Study: NCT03383627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: * The FreeStyle Libre Pro Flash Glucose Monitoring System is a professional continuous glucose monitoring (CGM) device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. The Freestyle Libre Pro device is FDA approved (PMA# P150021). Participants will use the FreeStyle Libre Pro Flash Glucose Monitoring device according to its approved use, on the back of the arm.~* CGM monitoring will be performed on Day 1 by placing the Freestyle Libre Pro on research subjects for intended use of 14 days.~* Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis.
Study: NCT00042289

Intervention type: DRUG
Intervention: lopinavir/ritonavir dosage #2
Description: lopinavir/ritonavir (Kaletra) 400/100mg twice a day

Intervention type: DRUG
Intervention: lopinavir/ritonavir dosage #2
Description: lopinavir/ritonavir (Kaletra) 400/100mg twice a day
Study: NCT01297309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPSP558
Description: All patients will inject NPSP558 individual titration of 25, 50, 75 or 100 μg SC QD into alternating thighs in the morning via a multidose injection pen device.
Study: NCT00042289

Intervention type: DRUG
Intervention: lopinavir/ritonavir dosage #2
Description: lopinavir/ritonavir (Kaletra) 400/100mg twice a day

Intervention type: DRUG
Intervention: lopinavir/ritonavir dosage #2
Description: lopinavir/ritonavir (Kaletra) 400/100mg twice a day

Intervention type: DRUG
Intervention: lopinavir/ritonavir dosage #2
Description: lopinavir/ritonavir (Kaletra) 400/100mg twice a day

Intervention type: DRUG
Intervention: lopinavir/ritonavir dosage #2
Description: lopinavir/ritonavir (Kaletra) 400/100mg twice a day

Intervention type: DRUG
Intervention: indinavir/ritonavir dosage #1
Description: indinavir/ritonavir 800/100mg twice a day

Intervention type: DRUG
Intervention: fosamprenavir/ritonavir
Description: fosamprenavir/ritonavir 700/100 mg twice a day

Intervention type: DRUG
Intervention: lopinavir/ritonavir dosage #3
Description: lopinavir/ritonavir (Kaletra) 533/133 mg twice a day

Intervention type: DRUG
Intervention: atazanavir/ritonavir dosage #1
Description: atazanavir/ritonavir 300/100 mg once a day

Intervention type: DRUG
Intervention: atazanavir/ritonavir dosage #1
Description: atazanavir/ritonavir 300/100 mg once a day

Intervention type: DRUG
Intervention: didanosine delayed release (Videx® EC)
Description: didanosine delayed release (Videx® EC) 400 mg once a day if weight \> 60 kg; 250 mg once a day if weight \< 60 kg

Intervention type: DRUG
Intervention: emtricitabine
Description: emtricitabine 200 mg once a day
Study: NCT05020301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: external meditation guided audio
Description: Examining DMN connectivity and CSF flow in external meditation state by External Meditation Instruction Audio.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: external meditation guided audio
Description: Examining DMN connectivity and CSF flow in external meditation state by External Meditation Instruction Audio.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: external meditation guided audio
Description: Examining DMN connectivity and CSF flow in external meditation state by External Meditation Instruction Audio.
Study: NCT00042289

Intervention type: DRUG
Intervention: tenofovir
Description: tenofovir 300 mg once a day

Intervention type: DRUG
Intervention: nelfinavir dosage #1
Description: nelfinavir \[625 mg tablets\] 1250 mg twice a day

Intervention type: DRUG
Intervention: nelfinavir dosage #1
Description: nelfinavir \[625 mg tablets\] 1250 mg twice a day

Intervention type: DRUG
Intervention: tipranavir/ritonavir
Description: tipranavir/ritonavir 500/200 mg twice a day

Intervention type: DRUG
Intervention: lopinavir/ritonavir dosage #4
Description: lopinavir/ritonavir (Kaletra) tablets 600/150 mg \[3 tablets\] twice a day

Intervention type: DRUG
Intervention: lopinavir/ritonavir dosage #4
Description: lopinavir/ritonavir (Kaletra) tablets 600/150 mg \[3 tablets\] twice a day

Intervention type: DRUG
Intervention: raltegravir
Description: raltegravir 400 mg twice a day

Intervention type: DRUG
Intervention: etravirine
Description: etravirine 200 mg twice a day

Intervention type: DRUG
Intervention: maraviroc
Description: maraviroc 150 mg or 300 mg twice a day

Intervention type: DRUG
Intervention: atazanavir/ritonavir dosage #2
Description: atazanavir/ritonavir 400/100mg once a day

Intervention type: DRUG
Intervention: tenofovir/atazanavir/ritonavir dosage #2
Description: tenofovir/atazanavir/ritonavir 300/400/100 mg once a day

Intervention type: DRUG
Intervention: nelfinavir dosage #2
Description: nelfinavir \[625 mg tablets\] 1875 mg twice a day

Intervention type: DRUG
Intervention: indinavir/ritonavir dosage #2
Description: indinavir/ritonavir 400/100 mg twice a day

Intervention type: DRUG
Intervention: rilpivirine
Description: rilpivirine (25 mg q.d.)

Intervention type: DRUG
Intervention: darunavir/ritonavir dosage #4
Description: darunavir/ritonavir once daily 800/100 mg q.d.
Study: NCT00488462

Intervention type: DEVICE
Group type: OTHER
Intervention: non-pneumatic anti-shock garment
Description: In the intervention arm, half of the study clinics will use the NASG when a patient meets the study criteria.
Study: NCT01495117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: 7.5% povidone iodine soaping 10% povidone iodine painting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Description: 4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
Study: NCT00443261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: SC azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 75 mg/m\^2 day 8 every 28 days
Study: NCT03159013

Intervention type: OTHER
Group type: OTHER
Intervention: Exposure
Description: Oral exposure: 0,025 mg/kg bw dissolved in oil, on day 1, with blood withdrawn on days 2,3,4.~Dermal exposure: 145 µl of commercial formulation (0,25 mg/kg bw) on 40 cm2 of forearm skin for 6 hours, on day 28, with blood withdrawn on days 29,30,31.

Intervention type: OTHER
Group type: OTHER
Intervention: Exposure
Description: Oral exposure: 0,025 mg/kg bw dissolved in oil, on day 1, with blood withdrawn on days 2,3,4.~Dermal exposure: 145 µl of commercial formulation (0,25 mg/kg bw) on 40 cm2 of forearm skin for 6 hours, on day 28, with blood withdrawn on days 29,30,31.
Study: NCT00870038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention: Paclitaxel eluting balloon (Elutax) + Genous stent
Description: Predilatation with paclitaxel-eluting balloon, then stenting of the lesion with Genous stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention: Uncoated balloon + Genous stent
Description: Predilatation with uncoated balloon, the stenting with Genous stent.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention: Drug eluting stent (Taxus stent)
Description: Predilatation with uncoated balloon, the placement of a Taxus stent.
Study: NCT04165733

Intervention type: DIAGNOSTIC_TEST
Intervention: Online questionnaire
Description: Clinical psychologists in Germany currently working with patients with mental disorders
Study: NCT01002742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Oral dosing should be delivered in 250 mg units. For those \< 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.~* Patients who weight \> 60 kg should receive MMF 1 gm PO/IV every 8 hours.~* Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.~* Patients who weight \<40 kg should receive 20 mg/kg IV or PO every 8 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dosing should be delivered in 250 mg units blinded placebo. For those \< 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.~* Patients who weight \> 60 kg should receive placebo 1 gm PO/IV every 8 hours.~* Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.~* Patients who weight \<40 kg should receive 20 mg/kg IV or PO every 8 hours.
Study: NCT02800772

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: acetic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study: NCT02766907

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cryopreserved amniotic membrane
Description: placement of cryopreserved amniotic membrane after routine debridement procedure for EBMD
Study: NCT04539691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnet
Description: Magnet or Sham is worn by subject in close proximity to their described maximum pain site

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magnet
Description: Magnet or Sham is worn by subject in close proximity to their described maximum pain site
Study: NCT01351064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHICA ADHD Module
Description: This module was added to CHICA to help diagnose and manage ADHD
Study: NCT00869219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevanac
Description: 1 drop of NEVANAC at random eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acular LS
Description: One drop of Acular LS
Study: NCT00168909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alfacalcidol
Description: alfacalcidol 1 µg once daily, oral, for 3 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo once daily, oral, for 3 years
Study: NCT00950976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: citrulline
Description: TID for 5 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lemonade
Description: TID for 5 days
Study: NCT01601951

Intervention type: OTHER
Intervention: Procedural, Bone Marrow concentrate injection
Description: This is strictly data collection and outcomes based. The procedure is not part of this study

Intervention type: OTHER
Intervention: Procedural, Bone Marrow concentrate injection
Description: This is strictly data collection and outcomes based. The procedure is not part of this study
Study: NCT00643344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Craving and Lifestyle Management through Mindfulness(CALMM+)
Description: MBSR is a program that provides systematic training in mindfulness meditation and gentle yoga as a self-regulation approach to reduce stress and improve medical and psychological symptoms. In this randomized controlled pilot study, we aim to test a 16-week intervention that further integrates diet and exercise into the CALMM program (CALMM+). This novel program, which includes elements drawn from MBSR, will be actively compared with the conventional diet and exercise group(TLC). Both groups will receive about 7 hours of in-class and out-of-class activities per week. The activities includes exercise, keeping dietary records, and stress reduction practices (if they are assigned to the intervention group).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Craving and Lifestyle Management through Mindfulness(CALMM+)
Description: MBSR is a program that provides systematic training in mindfulness meditation and gentle yoga as a self-regulation approach to reduce stress and improve medical and psychological symptoms. In this randomized controlled pilot study, we aim to test a 16-week intervention that further integrates diet and exercise into the CALMM program (CALMM+). This novel program, which includes elements drawn from MBSR, will be actively compared with the conventional diet and exercise group(TLC). Both groups will receive about 7 hours of in-class and out-of-class activities per week. The activities includes exercise, keeping dietary records, and stress reduction practices (if they are assigned to the intervention group).
Study: NCT03222440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
Study: NCT00250081

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper Extremity Tendon transfer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin injections in Upper Extremity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regularly ongoing therapy
Study: NCT03201848

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given to subject will be adjusted by body weight (\<10kg, Placebo given to subject will be adjusted by body weight(\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day;) .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaiqihuang Granule
Description: Huaiqihuang Granule given to subject will be adjusted by body weight (\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Huaiqihuang Granule
Description: Huaiqihuang Granule given to subject will be adjusted by body weight (\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day)
Study: NCT02372097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 25mg, 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 25mg, 50mg
Study: NCT02111967

Intervention type: OTHER
Intervention: Questionnaire administration

Intervention type: OTHER
Intervention: Questionnaire administration

Intervention type: OTHER
Intervention: Laboratory biomarker analysis

Intervention type: OTHER
Intervention: Laboratory biomarker analysis
Study: NCT02528253

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Week 16; tanezumab 5mg SC
Description: Placebo SC injection every 8 weeks for 2 injections followed by tanezumab 5 mg injection every 8 weeks for 5 injections

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Week 16, tanezumab 10 mg SC
Description: Placebo SC injection every 8 weeks for 2 injections, followed by tanezumab 10 mg SC injection for 5 injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg SC
Description: Tanezumab 5 mg SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 10 mg SC
Description: Tanezumab 10 mg SC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol PR oral
Description: Tramadol PR oral
Study: NCT01536652

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Prescription at the discretion of the treating physician
Study: NCT04397029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SureTouch
Description: The first group will consist of 70 women who are believed to be free of masses, recruited during a screening mammography appointment.~The second group will include 125 women presenting for diagnostic mammography and/or biopsy appointment with known masses identified on mammogram, ultrasound or both.~Both groups will receive breast cancer screening with mammography and SureTouch.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SureTouch
Description: The first group will consist of 70 women who are believed to be free of masses, recruited during a screening mammography appointment.~The second group will include 125 women presenting for diagnostic mammography and/or biopsy appointment with known masses identified on mammogram, ultrasound or both.~Both groups will receive breast cancer screening with mammography and SureTouch.
Study: NCT04347278

Intervention type: DRUG
Intervention: Patients with the treatment agains COVID19
Description: Data will be collected from patients who receive any of the treatments included in the Technical Document. Manejo clínico del COVID-19: tratamiento médico of the Ministry of Health, and Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2 of the AEMPS, either as antivirals or as treatment of the inflammatory process in patients with SARS, or others as they arise.
Study: NCT02759562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered via subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered via subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered via subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered via subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered via subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via subcutaneous injection
Study: NCT01746810

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body RT and IRGA
Description: SABR Treatment with Dose escalation: Group 1: 40 Gy/5 fractions Group 2: 45 Gy/5 fractions Group 3: 50 Gy/5 fractions then IRGA procedure 1 week later with repeat lung biopsies, serum studies
Study: NCT05020301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: internal meditation guided audio
Description: Examining DMN connectivity and CSF flow in external meditation state by Internal Meditation Instruction Audio.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: internal meditation guided audio
Description: Examining DMN connectivity and CSF flow in external meditation state by Internal Meditation Instruction Audio.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: internal meditation guided audio
Description: Examining DMN connectivity and CSF flow in external meditation state by Internal Meditation Instruction Audio.
Study: NCT04580043

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habit Override Practice
Description: Computerized brain training to provide practice in overriding avoidance habits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit Override Practice
Description: Computerized brain training to provide practice in overriding avoidance habits.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Non-invasive method for temporary, focal stimulation of brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Non-invasive method for temporary, focal stimulation of brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: Computer-based task practice in a non-active/inert task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham Training
Description: Computer-based task practice in a non-active/inert task.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Sham stimulation of non-brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Sham stimulation of non-brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
Study: NCT02678312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: Enalapril tablets: 2.5 mg, 5 mg, 10 mg dosage strengths
Study: NCT03240562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: serratus anterior plane block
Description: before surgery :ultrasound-guided serratus anterior plane block

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: patient controlled analgesia
Description: two groups have same intravenous patient controlled analgesia
Study: NCT02678312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril tablets: 2.5 mg, 5 mg, 10 mg dosage strengths
Study: NCT03240562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patient controlled analgesia
Description: two groups have same intravenous patient controlled analgesia
Study: NCT02678312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of LCZ696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Enalapril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules), tablets: 50 mg, 100 mg, 200 mg dosage strengths
Study: NCT04946162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil Pill
Description: Each patient will be given tadalafil 40 mg one time
Study: NCT02549963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN Left Atrial Appendage Occlusion Device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Study: NCT02359032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6858
Description: Oral tablets
Study: NCT04297410

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-I&T Radionuclide
Description: Each patient will receive two single doses of 7.4 GBq 177-Lu-PSMA-I\&T treatments. The treatments will be given intravenously, 2 weeks apart starting 12 weeks prior to radical prostatectomy.
Study: NCT03628599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lenses
Description: Water Gradient silicon hydrogel daily disposable contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon A contact lenses
Description: Silicon hydrogel daily disposable contact lenses with HydraLuxe™ Technology
Study: NCT02359032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6858
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6858
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6858
Description: Oral tablets